Komal Jhaveri

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 19 papers. Top paper: “Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT”.

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT

Radiology(2020)10.1148/radiol.2020192828

N/A

2.1DataRank · unranked

70 citations

Jorge A. Carrasquillo, Christopher C. Riedl, Randy Yeh, Vaios Hatzoglou, Dara S. Ross +7 more

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00251-7

N/A

1.4DataRank · unranked

36 citations

Gerald Batist, Funda Meric‐Bernstam, Peter Kabos, Iben Spanggaard, Aňa Lluch +22 more

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003

N/A

1.4DataRank · unranked

61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1796

N/A

0.680DataRank · unranked

24 citations

Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni +17 more

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2657

N/A

0.557DataRank · unranked

40 citations

Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk +16 more

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

Breast Cancer Research and Treatment(2020)10.1007/s10549-020-05726-y

N/A

0.550DataRank · unranked

38 citations

Dulce M. Barrios, Victoria Blinder, Jacqueline Bromberg, Pamela Drullinsky, Samuel A. Funt +10 more

First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3704

N/A

0.524DataRank · unranked

32 citations

Christina Pressl, Nagavarakishore Pillarsetty, Milan Grkovski, Shanu Modi, Komal Jhaveri +18 more

Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group

Cancer Treatment Reviews(2025)10.1016/j.ctrv.2025.103001

N/A

0.406DataRank · unranked

14 citations

Sherry Shen, Carmen Criscitiello, Rita A. Mukhtar, Lauren A. Gamble, Elena Guerini‐Rocco +20 more

HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1052

N/A

0.292DataRank · unranked

6 citations

Fresia Pareja, Komal Jhaveri, Elaine M. Walsh, Geoffrey Y. Ku, Steven B. Maron +7 more

Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1063

N/A

0.241DataRank · unranked

4 citations

Diana G. Wang, Victoria Blinder, Jacqueline Bromberg, Pamela Drullinsky, Samuel A. Funt +10 more

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Molecular Oncology(2021)10.1002/1878-0261.13150

N/A

0DataRank · unranked

21 citations

Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce +27 more

Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors

Cancer Research(2021)10.1158/0008-5472.can-20-3232

N/A

0DataRank · unranked

35 citations

Guotai Xu, Fan Wu, Flavia Michelini, Carmen Chan, Xuan Qu +16 more

Accelerating drug development in breast cancer: New frontiers for ER inhibition

Cancer Treatment Reviews(2022)10.1016/j.ctrv.2022.102432

N/A

0DataRank · unranked

52 citations

Elaine M. Walsh, Jacqueline J. Tao, Sarat Chandarlapaty, Komal Jhaveri, Emanuela Ferraro

Epichaperome-targeted Myocardial Imaging by 124I-PU-H71 PET

Research Square(2023)10.21203/rs.3.rs-3278571/v1

N/A

0DataRank · unranked

0 citations

Milan Grkovski, Kevin D. Staton, Susana Ravassa, Kwaku Domfe, H. William Strausś +13 more

Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial

Clinical Lung Cancer(2024)10.1016/j.cllc.2024.12.003

N/A

0DataRank · unranked

4 citations

A. Martinez Bueno, Christophe Dooms, Komal Jhaveri, Maria de Miguel, Sarina A. Piha‐Paul +12 more

Data from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

(2024)10.1158/1078-0432.c.7077719

N/A

0DataRank · unranked

0 citations

Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni +17 more

Data from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

(2024)10.1158/1078-0432.c.7077719.v1

N/A

0DataRank · unranked

0 citations

Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni +17 more

Data from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

(2023)10.1158/1078-0432.c.6529761.v1

N/A

0DataRank · unranked

0 citations

Christina Pressl, Nagavarakishore Pillarsetty, Milan Grkovski, Shanu Modi, Komal Jhaveri +18 more

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3135

N/A

0DataRank · unranked

0 citations

Yonina R. Murciano‐Goroff, Justin Jee, Maria E. Arcila, Darren J. Buonocore, Jianjiong Gao +15 more